Showing 5761-5770 of 6808 results for "".
- First EB Patient Enrolled in PK Study of Diacerein 1% Ointmenthttps://practicaldermatology.com/news/first-eb-patient-enrolled-in-pk-study-of-diacerein-1-ointment/2457716/The first patient has been enrolled in a new Phase 1 study evaluating the pharmacokinetics (PK) and safety of Castle Creek Pharmaceuticals’ diacerein 1% ointment (CCP-020) under maximum use conditions in patients with epidermolysis bullosa (EB)
- CBD Naturals to Introduce New Skincare Linehttps://practicaldermatology.com/news/cbd-naturals-to-introduce-new-skincare-line/2457717/Delivering natural beauty from the inside out, CBD Naturals® will introduce Floré™, a prestigious new line of skincare products, at the International Cannabis Business Conference in Vancouver on June 25. Floré™ incorporates cutting-edge ingredient formulas that
- Restoration Robotics Launches Continuing Education Master Class for ARTAS Systemhttps://practicaldermatology.com/news/restoration-robotics-launches-continuing-education-master-class-for-artas-system/2457729/Restoration Robotics, Inc. is launching a continuing education Master Class Series for its ARTAS® Robotic Hair Restoration System to train physicians on best practices and the most up-to-date techniques for the technology. The Master Class Series will enable users to provide exceptional
- ThermiVa: First-ever Data Show Vaginal Regenerationhttps://practicaldermatology.com/news/thermiva-first-ever-data-show-vaginal-regeneration/2457730/Thermi’s ThermiVa® device has been shown to deliver significant improvements in common vaginal disorders and improve sexual satisfaction, according to a study published in Dermatologic Surgery. Since it was cleared by the FDA in 2013, ThermiVa has been used
- Opdivo Data: Superior Recurrence-Free Survival Versus Ipilimumabhttps://practicaldermatology.com/news/opdivo-data-superior-recurrence-free-survival-versus-ipilimumab/2457734/Updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo (nivolumab, Bristol-Myers Squibb Company) versus Yervoy (ipilimumab, Bristol-Myers Squibb Company) in patients with stage IIIB/C or stage IV melanoma who are at high ri
- Gryphon Investors Makes Majority Investment in Water's Edge Dermatologyhttps://practicaldermatology.com/news/gryphon-investors-makes-majority-investment-in-waters-edge-dermatology/2457741/Gryphon Investors has made a majority investment in Water’s Edge Dermatology. Terms of the transaction were not disclosed. Gryphon Investors is a San Francisco-based middle market private equity firm. A leading provider of comprehensive dermatology services in over 30
- Avon Receives Patents for Rotational Infinite Effects Skincare Technologyhttps://practicaldermatology.com/news/avon-receives-patents-for-rotational-infinite-effects-skincare-technology/2457739/Avon has been issued two new patents for new technology currently included in the ANEW Reversalist Infinite Effects and most recently the ANEW Ultimate Infinite Effects products. The rotational regimen is designed to
- New CFO at Evolus, Inc.https://practicaldermatology.com/news/new-cfo-at-evolus-inc/2457744/Lauren Silvernail is the new Chief Financial Officer and Executive Vice President, Corporate Development at Evolus, Inc. Silvernail joins Evolus from Revance Therapeutics where she most recently served as Chief Financial Officer and Chief Business Officer. Prior to her time at Revance The
- DermTech: Carcinome Clinical Study Enrollment Completehttps://practicaldermatology.com/news/dermtech-carcinome-clinical-study-enrollment-complete/2457745/DermTech, Inc., the global leader in non-invasive molecular dermatology, announced completion of enrollment in the Carcinome™ clinical study. The goal of the Carcinome™ study is to develop a non-invasive genomic test to differentiate basal cell carcinoma (BCC) and squamous cell
- Severe AD Linked to CV Risk in Large Trialhttps://practicaldermatology.com/news/severe-ad-linked-to-cv-risk-in-large-trial/2457748/Eczema now joins the list of inflammatory conditions linked to cardiovascular risk. British researchers report that individuals with severe eczema may be at greater risk for heart attack, stroke and atrial fibrillation. Their study appears in the